Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours

被引：0
|
作者：
Jason D. Lickliter
Mark Voskoboynik
Linda Mileshkin
Hui K. Gan
Ganessan Kichenadasse
Kathy Zhang
Maggie Zhang
Zhiyu Tang
Michael Millward
机构：
[1] Nucleus Network,Department of Medicine
[2] Central Clinical School,undefined
[3] Monash University,undefined
[4] Peter MacCallum Cancer Centre-East Melbourne,undefined
[5] Olivia Newton-John Cancer Wellness and Research Centre,undefined
[6] Austin Hospital,undefined
[7] Heidelberg,undefined
[8] La Trobe University School of Cancer Medicine,undefined
[9] University of Melbourne,undefined
[10] Flinders Centre for Innovation in Cancer,undefined
[11] Flinders Medical Centre,undefined
[12] BeiGene USA,undefined
[13] Inc.,undefined
[14] Linear Clinical Research & University of Western Australia,undefined
来源：
British Journal of Cancer | 2022年 / 126卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：576 / 585
页数：9
相关论文
共 50 条
  • [1] Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours
    Lickliter, Jason D.
    Voskoboynik, Mark
    Mileshkin, Linda
    Gan, Hui K.
    Kichenadasse, Ganessan
    Zhang, Kathy
    Zhang, Maggie
    Tang, Zhiyu
    Millward, Michael
    BRITISH JOURNAL OF CANCER, 2022, 126 (04) : 576 - 585
  • [2] Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours
    Jason D. Lickliter
    Mark Voskoboynik
    Linda Mileshkin
    Hui K. Gan
    Ganessan Kichenadasse
    Kathy Zhang
    Maggie Zhang
    Zhiyu Tang
    Michael Millward
    British Journal of Cancer, 2022, 126 : 310 - 310
  • [3] Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours (Dec, 10.1038/s41416-021-01632-2, 2021)
    Lickliter, Jason D.
    Voskoboynik, Mark
    Mileshkin, Linda
    Gan, Hui K.
    Kichenadasse, Ganessan
    Zhang, Kathy
    Zhang, Maggie
    Tang, Zhiyu
    Millward, Michael
    BRITISH JOURNAL OF CANCER, 2022, 126 (02) : 310 - 310
  • [4] Safety, antitumor activity, and pharmacokinetics (PK) of pamiparib (BGB-290), a PARP1/2 inhibitor, in patients (pts) with advanced solid tumours: Updated phase I dose-escalation/expansion results
    Voskoboynik, M.
    Mileshkin, L.
    Gan, H.
    Millward, M.
    Au-Yeung, G.
    Meniawy, T. M.
    Kichenadasse, G.
    Zhang, K.
    Zhang, M.
    Mu, S.
    Lickliter, J. D.
    ANNALS OF ONCOLOGY, 2019, 30
  • [5] A phase I, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of ADCT-601 in patients with advanced solid tumours
    Tolcher, A. W.
    Falchook, G.
    Bendell, J. C.
    Ungar, D.
    Boni, J.
    Chao, G.
    Patel, M. R.
    ANNALS OF ONCOLOGY, 2019, 30 : 176 - +
  • [6] Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial
    Friedlander, Michael
    Meniawy, Tarek
    Markman, Ben
    Mileshkin, Linda
    Harnett, Paul
    Millward, Michael
    Lundy, Joanne
    Freimund, Alison
    Norris, Christie
    Mu, Song
    Wu, John
    Paton, Virginia
    Gao, Bo
    LANCET ONCOLOGY, 2019, 20 (09): : 1306 - 1315
  • [7] Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial
    Patnaik, Amita
    Weiss, Glen J.
    Rasco, Drew W.
    Blaydorn, Lisa
    Mirabella, Amy
    Beeram, Murali
    Guo, Wei
    Lu, Sharon
    Danaee, Hadi
    McEachern, Kristen
    Im, Ellie
    Sachdev, Jasgit C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (01) : 93 - 103
  • [8] A first-in-human, phase 1a/1b, open-label, dose-escalation and expansion study to investigate the safety, pharmacokinetics, and antitumor activity of the RAF dimer inhibitor BGB-3245 in patients with advanced or refractory tumors
    Schram, Alison M.
    Subbiah, Vivek
    Sullivan, Ryan
    Cosman, Rasha
    Liu, Jia
    Sbar, Eric I.
    Thuy Hoang
    Chen, Jiarong
    Johnson, Mark
    Amoruccio, Vincent
    Shearer, Todd
    Kamal, Adeela
    Lewis, Jocelyn
    Shao, Wenlin
    Edris, Badreddin
    Luo, Lusong
    Desai, Jayesh
    CANCER RESEARCH, 2023, 83 (08)
  • [9] A PHASE 1A/1B DOSE-ESCALATION STUDY OF INTRAVENOUSLY ADMINISTERED SB 11285 ALONE AND IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
    Abbas, A.
    Strauss, J.
    Janku, F.
    Karim, R.
    Olszanski, A.
    Luke, J. J.
    Leach, K.
    Iyer, R.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A7 - A8
  • [10] A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours
    Li, Xiaoyu
    Qiu, Meng
    Wang, ShengJun
    Zhu, Hong
    Feng, Bi
    Zheng, Li
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (03) : 593 - 604
12345